tradingkey.logo


tradingkey.logo


Sellas Life Sciences Group Inc

SLS
2.895USD
+0.255+9.66%
取匕時間 ET15分遅れの株䟡
362.10M時䟡総額
損倱額盎近12ヶ月PER


Sellas Life Sciences Group Inc

2.895
+0.255+9.66%

詳现情報 Sellas Life Sciences Group Inc 䌁業名

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.

Sellas Life Sciences Group Incの䌁業情報


䌁業コヌドSLS
䌚瀟名Sellas Life Sciences Group Inc
䞊堎日Mar 12, 2008
最高経営責任者「CEO」Stergiou (Angelos M)
埓業員数15
蚌刞皮類Ordinary Share
決算期末Mar 12
本瀟所圚地7 Times Square
郜垂NEW YORK
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号10036
電話番号16462005278
りェブサむトhttps://www.sellaslifesciences.com/
䌁業コヌドSLS
䞊堎日Mar 12, 2008
最高経営責任者「CEO」Stergiou (Angelos M)

Sellas Life Sciences Group Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Angelos M. Stergiou, M.D.
Dr. Angelos M. Stergiou, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
108.88K
-79.44%
Ms. Katherine Bach Kalin
Ms. Katherine Bach Kalin
Independent Director
Independent Director
93.80K
+208.55%
Dr. Dragan Cicic, M.D.
Dr. Dragan Cicic, M.D.
Senior Vice President, Chief Development Officer
Senior Vice President, Chief Development Officer
50.33K
-73.28%
Mr. John Thomas Burns, CPA
Mr. John Thomas Burns, CPA
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
48.60K
-77.19%
Ms. Jane Wasman, J.D.
Ms. Jane Wasman, J.D.
Independent Director
Independent Director
30.40K
+192.31%
Mr. Robert L. Van Nostrand, CPA
Mr. Robert L. Van Nostrand, CPA
Independent Director
Independent Director
20.40K
+96.15%
Dr. David A. Scheinberg, M.D., Ph.D.
Dr. David A. Scheinberg, M.D., Ph.D.
Independent Director
Independent Director
10.58K
-38.05%
Mr. John W. Varian
Mr. John W. Varian
Independent Chairman of the Board
Independent Chairman of the Board
10.40K
-38.46%
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Angelos M. Stergiou, M.D.
Dr. Angelos M. Stergiou, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
108.88K
-79.44%
Ms. Katherine Bach Kalin
Ms. Katherine Bach Kalin
Independent Director
Independent Director
93.80K
+208.55%
Dr. Dragan Cicic, M.D.
Dr. Dragan Cicic, M.D.
Senior Vice President, Chief Development Officer
Senior Vice President, Chief Development Officer
50.33K
-73.28%
Mr. John Thomas Burns, CPA
Mr. John Thomas Burns, CPA
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
48.60K
-77.19%
Ms. Jane Wasman, J.D.
Ms. Jane Wasman, J.D.
Independent Director
Independent Director
30.40K
+192.31%
Mr. Robert L. Van Nostrand, CPA
Mr. Robert L. Van Nostrand, CPA
Independent Director
Independent Director
20.40K
+96.15%

収益内蚳

䌚瀟から関連デヌタがただ開瀺されおいたせん。
䌚瀟から関連デヌタがただ開瀺されおいたせん。
事業別
地域別
䌚瀟から関連デヌタがただ開瀺されおいたせん。

株䞻

曎新時刻: Sun, Nov 16
曎新時刻: Sun, Nov 16
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
The Vanguard Group, Inc.
4.80%
Anson Funds Management LP.
4.24%
BlackRock Institutional Trust Company, N.A.
3.64%
Marshall Wace LLP
1.66%
Geode Capital Management, L.L.C.
1.59%
他の
84.07%
株䞻統蚈
株䞻統蚈
比率
The Vanguard Group, Inc.
4.80%
Anson Funds Management LP.
4.24%
BlackRock Institutional Trust Company, N.A.
3.64%
Marshall Wace LLP
1.66%
Geode Capital Management, L.L.C.
1.59%
他の
84.07%
皮類
株䞻統蚈
比率
Investment Advisor
11.84%
Investment Advisor/Hedge Fund
5.39%
Hedge Fund
5.29%
Research Firm
0.51%
Individual Investor
0.26%
Bank and Trust
0.09%
Pension Fund
0.04%
Insurance Company
0.03%
他の
76.55%

機関投資家保有株


曎新時刻: Wed, Oct 1
曎新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株匏数
比率
倉動額
2025Q3
135
27.86M
26.46%
+4.71M
2025Q2
100
16.82M
16.86%
+5.40M
2025Q1
95
15.37M
15.79%
+4.85M
2024Q4
82
6.32M
8.71%
-3.29M
2024Q3
79
5.54M
8.62%
-2.91M
2024Q2
81
6.60M
15.25%
-2.78M
2024Q1
80
10.46M
22.59%
+5.00M
2023Q4
78
5.95M
19.06%
+1.91M
2023Q3
79
3.15M
11.52%
-1.61M
2023Q2
83
3.51M
12.82%
-1.46M
詳现を芋る

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
The Vanguard Group, Inc.
6.65M
6.32%
+3.82M
+134.38%
Jun 30, 2025
Anson Funds Management LP.
275.00K
0.26%
-7.30M
-96.37%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.17M
3.96%
+3.73M
+855.11%
Jun 30, 2025
Marshall Wace LLP
2.72M
2.58%
+2.70M
+23549.97%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.20M
2.09%
+1.38M
+168.20%
Jun 30, 2025
State Street Investment Management (US)
1.11M
1.06%
+835.68K
+301.66%
Jun 30, 2025
Nuveen LLC
971.33K
0.92%
+971.33K
--
Jun 30, 2025
Susquehanna International Group, LLP
1.49M
1.41%
+800.98K
+116.30%
Jun 30, 2025
Northern Trust Investments, Inc.
683.13K
0.65%
+518.74K
+315.55%
Jun 30, 2025
Morgan Stanley Smith Barney LLC
538.78K
0.51%
+510.23K
+1787.21%
Jun 30, 2025
詳现を芋る

関連ETF


曎新時刻: Tue, Dec 2
曎新時刻: Tue, Dec 2
銘柄名
比率
Vanguard US Momentum Factor ETF
0.08%
iShares Micro-Cap ETF
0.04%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 ETF
0.01%
iShares Russell 2000 Growth ETF
0.01%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
Global X Russell 2000 ETF
0.01%
iShares Core S&P Total U.S. Stock Market ETF
0%
Vanguard US Momentum Factor ETF
比率0.08%
iShares Micro-Cap ETF
比率0.04%
Proshares Ultra Russell 2000
比率0.01%
iShares Russell 2000 ETF
比率0.01%
iShares Russell 2000 Growth ETF
比率0.01%
ProShares UltraPro Russell2000
比率0.01%
ProShares Hedge Replication ETF
比率0.01%
Global X Russell 2000 ETF
比率0.01%
iShares Core S&P Total U.S. Stock Market ETF
比率0%

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
皮類
比率
デヌタなし
日付
皮類
比率
デヌタなし

よくある質問

Sellas Life Sciences Group Incの䞊䜍5名の株䞻は誰ですか


Sellas Life Sciences Group Incの䞊䜍5名の株䞻は以䞋のずおりです。
The Vanguard Group, Inc.は6.65M株を保有しおおり、これは党䜓の6.32%に盞圓したす。
Anson Funds Management LP.は275.00K株を保有しおおり、これは党䜓の0.26%に盞圓したす。
BlackRock Institutional Trust Company, N.A.は4.17M株を保有しおおり、これは党䜓の3.96%に盞圓したす。
Marshall Wace LLPは2.72M株を保有しおおり、これは党䜓の2.58%に盞圓したす。
Geode Capital Management, L.L.C.は2.20M株を保有しおおり、これは党䜓の2.09%に盞圓したす。

Sellas Life Sciences Group Incの株䞻タむプ䞊䜍3皮は䜕ですか


Sellas Life Sciences Group Incの株䞻タむプ䞊䜍3皮は、
The Vanguard Group, Inc.
Anson Funds Management LP.
BlackRock Institutional Trust Company, N.A.

Sellas Life Sciences Group IncSLSの株匏を保有しおいる機関の数はいく぀ですか


2025Q3時点で、Sellas Life Sciences Group Incの株匏を保有しおいる機関は135瀟あり、保有株匏の総垂堎䟡倀は玄27.86Mで、党䜓の26.46%を占めおいたす。2025Q2ず比范しお、機関の持ち株は9.60%増加しおいたす。

Sellas Life Sciences Group Incの最倧の収益源は䜕ですか


--においお、--郚門がSellas Life Sciences Group Incにずっお最倧の収益を生み出しおおり、その金額は--で、党収益の--%を占めおいたす。
KeyAI
î™